Rituximab (RTX) for Disease Modifying Anti Rheumatic Drug (DMARD) Non-responders in Pakistan: The Pakistan Rituximab Study (PARIS) (PARIS)

Efficacy and Safety of Rituximab in Pakistani Patients With Rheumatoid Arthritis (RA)

A study to determine the efficacy and safety of rituximab in Pakistani patients with rheumatoid arthritis (RA) who have been inadequately controlled with standard disease modifying anti rheumatic drugs (DMARDs).

Study Overview

• Status: Completed
• Conditions: Rheumatoid Arthritis
• Intervention / Treatment: Drug: Rituximab

Detailed Description

Enrolled subjects with inadequately-controlled RA had their disease activity level assessed before initiation of therapy and at intervals of 6 months and 12 months thereafter. Standardized disease activity scores like the Disease Activity Score-28 (DAS 28) were used for determining remission or otherwise of the disease. The American College of Rheumatology (ACR) 20, 50 and 70 response scores and the European League of Associations for Rheumatology (EULAR) Response Criteria for RA were used to determine the percentage improvement in the individual subject's condition at the same intervals. The former utilizes a set of assessments to determine if, after a given therapy, there has been a 20, 50 or 70% improvement in the aggregate scores as compared to the baseline and the latter utilizes calculated improvements in the DAS 28 score to determine if the response to treatment has been good, moderate or none. Both of these have been validated and approved for use by the ACR and EULAR respectively.

The study enrollment period was from 1st January 2010 till 31st December 2010. Observation period was 12 months from the enrollment date for each subject. The final results are being reported here.

• Study Type: Interventional
• Enrollment (Actual): 74
• Phase: Phase 4

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Able and willing to give written informed consent.
2. Men and women aged 18-80 years, inclusive.
3. Patients with RA for at least 6 months.
4. DAS28 score > 3.70 at baseline.
5. Inadequate response to methotrexate (MTX), for at least 4 weeks using a stable dose of 15mg/week. Glucocorticoids (<10 mg/day prednisone or equivalent) permitted if stable for at least 4 weeks prior to baseline.
6. Use of Non-steroidal anti-inflammatory drugs (NSAIDs) permitted if stable dose for at least 2 weeks prior to baseline.
7. Patients of reproductive potential (males and females) must be willing to use a reliable method of contraception (e.g. contraceptive pill, intrauterine device (IUD) or a physical barrier) during the study and for 12 months after last Rituximab administration.
8. If female and of childbearing potential, a negative serum pregnancy test within 2 weeks prior to baseline.

Exclusion Criteria:

Exclusion Criteria Related to RA

1. Bed bound or wheelchair bound patients.
2. Rheumatic autoimmune disease other than RA, or significant systemic involvement secondary to RA

Exclusions Related to Medications

1. History of severe allergic or anaphylactic reactions to a biologic agent or known hypersensitivity to any component of Rituximab or to murine proteins.
2. Previous treatment with any approved or investigational biologic agent for RA.
3. Concurrent treatment with any biologic agent for any indication.
4. Receipt of any vaccine within 4 weeks prior to baseline (it was recommended that a patient's vaccination record and the need for immunization prior to receiving Rituximab should be carefully investigated).
5. Intolerance to or contraindications to drugs required for the treatment of adverse event of Rituximab (e.g., paracetamol, anti-histamines, hydrocortisone, anti-emetics or histamine-receptor 1 (H1) blockers).
6. Intra-articular or parenteral glucocorticoids within 4 weeks prior to baseline.

Exclusions for General Safety/Health

1. Any surgical procedure, including bone / joint surgery / synovectomy (including joint fusion or replacement) within 12 weeks prior to baseline or planned within 24 weeks of randomization.
2. Evidence of any severe or significant medical condition(s) or disease(s) that, in the view of the investigator, prohibited participation in the study.
3. Evidence of significant uncontrolled concomitant disease such as, but not limited to, nervous system, renal, hepatic, endocrine or gastrointestinal disorders which, in the investigator's opinion, would have precluded patient participation.
4. Significant cardiac (heart failure of New York Heart Association (NYHA) class IV) or pulmonary disease (including obstructive pulmonary disease).
5. Known active and/or severe infection (e.g. tuberculosis, sepsis and opportunistic infections), or a known active infection of any kind (excluding fungal infections of nail beds), or any major episode of infection requiring hospitalization or treatment with intravenous (IV) anti-infectives within 4 weeks prior to baseline or completion of oral anti-infectives within 2 weeks prior to baseline.
6. History of serious recurrent or chronic infection. (for screening for a chest infection a chest radiograph will be performed at screening if not performed within 12 weeks prior to screening).
7. Primary or secondary immunodeficiency (history of, or currently active), including known history of human immunodeficiency (HIV) infection.
8. Pregnancy or breast feeding.
9. Known history of active cancer during the past 5 years, including solid tumours, hematological malignancies and carcinoma in situ (except basal cell and squamous cell carcinoma of the skin that have been excised and cured).
10. Currently active alcohol or drug abuse or history of alcohol or drug abuse within 24 weeks prior to baseline.

Exclusion criteria related to laboratory findings:

1. Positive serum human chorionic gonadotropin measured within two weeks prior to the first infusion of study drug
2. Positive test for hepatitis B surface antigen (HBsAg) or for hepatitis C serology
3. Positive hepatitis B core antibody (HBcAb) associated with positive hepatitis B virus (HBV) detection (> 29 IU/L or > 169 copies/mL)
4. Hemoglobin < 8.0 g/dL
5. Absolute neutrophil count < 1.5 × 103/μL
6. Concentration of serum immunoglobulin G (IgG) and/or immunoglobulin M (IgM) below 5.0 and 0.40 mg/mL, respectively.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

OTHER: Single Arm; Treatment with Rituximab in RA patients showing inadequate response to standard DMARDs

Drug: Rituximab; Rituximab was administered as an intravenous infusion as per approved protocol on Day 1 and day 14. The protocol stipulated the administration of intravenous hydrocortisone 100 mg and oral pheniramine maleate 43.5 mg as pre-medication. The Rituximab itself was given as a 1 gm infusion slowly over a period of 4-6 hours. This was done either by a specialist nurse or a trained doctor.; Other Names: RTX

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Improvement in Disease Activity Assessment Score (DAS-28)	To determine the percentage of previously inadequately-controlled RA patients achieving improvement in their disease activity level post treatment with Rituximab at 6 months interval using Disease Activity Score in 28 selected joints (DAS-28).	6 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Status of disease activity level using DAS 28 score	To determine the percentage of such RA patients achieving improvement in their disease activity level post treatment at 12 months interval using DAS-28.	12 months
Status of disease response to treatment using the ACR 20/50/70 response criteria	Using the ACR 20/50/70 response criteria	12 months
Status of disease response to treatment using the EULAR response criteria	using the EULAR response criteria	12 months
Documenting serious adverse events during the trial period	Any event leading to hospitalization or death during the trial period	12 months

Collaborators and Investigators

• Sponsor: Prof. Abid Z. Farooqi
• Collaborators: Aga Khan University; Fatima Memorial Hospital; Fauji Foundation Hospital, Rawalpindi
• Investigators: Principal Investigator: Abid Z Farooqi, FRCPI, Pakistan Institute of Medical Sciences

Study record dates

Study Major Dates

• Study Start: January 1, 2010
• Primary Completion (ACTUAL): July 1, 2011
• Study Completion (ACTUAL): December 1, 2012

Study Registration Dates

• First Submitted: March 6, 2016
• First Submitted That Met QC Criteria: April 6, 2016
• First Posted (ESTIMATE): April 7, 2016

Study Record Updates

• Last Update Posted (ESTIMATE): April 7, 2016
• Last Update Submitted That Met QC Criteria: April 6, 2016
• Last Verified: April 1, 2016

More Information

Terms related to this study

• Keywords: RA; Pakistan, Rituximab
• Additional Relevant MeSH Terms: Immune System Diseases; Autoimmune Diseases; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Connective Tissue Diseases; Arthritis; Arthritis, Rheumatoid; Physiological Effects of Drugs; Antirheumatic Agents; Antineoplastic Agents; Immunologic Factors; Antineoplastic Agents, Immunological; Rituximab
• Other Study ID Numbers: ML25190

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO